the unique attomarker platform
The core Attomarker technology is an array of gold nanoparticles which are printed into an array of sensors spots over which the blood sample flows. The spots are illuminated from below to produce scattered light that changes with the mass of biomarker on the surface of the gold nanoparticles, Figure 1. The mass sensing is unique because it allows a proper measurement to be made that is fully quantitative. This will set the new global standard for biomarker tests with all laboratories giving answers in standard units and the end to local standards.
The future of Attomarker is to develop the panels of tests that make a difference.
A suite of different chips is currently in our rapid development pipeline including food allergy screening not just for IgE the component that cause allergic rection, but also IgG that protects against allergy and rises as people become desensitised. We are also developing a Fatty Liver Test that looks at the state of the liver from healthy through the onset of type 2 diabetes to cirrhosis. Finally, a full profile of the hormones of the menstrual cycle will help us to understand properly fertility and hormone replacement therapy in the menopause.
The LISCAR 7 will include development for the ward and Intensities Care Units to take blood samples from the standard vacutainer blood collection method and prepare the blood before testing with an incorporate robot.
Attomarker is also currently developing a handheld version of the device with the same tests, targeting launch in early 2023.
Available early 2023